vimarsana.com

Latest Breaking News On - Global product development at roche - Page 1 : vimarsana.com

Ocrelizumab Demonstrates Near-Complete Suppression of Relapses for Multiple Sclerosis

Ocrelizumab (Ocrevus; Roche) is being investigated as a twice yearly 10-minute subcutaneous injection compared to the intravenous infusion formulation.

United statesOcrelizumab ocrevusLevi garrawayScott newsomeJohns hopkins university school of medicineNational multiple sclerosis societyGlobal product development at rocheAmerican academyNeurology annual meetingGlobal product developmentJohns hopkins university school

Study Examining Glofitamab With GemOX in Patients With R/R DLBCL Meets Primary Endpoint

Previously, glofitamab had received an accelerated approval for patients with relapsed or refractory diffuse large B-cell lymphoma who received 2 or more prior lines of systemic therapy.

Mabthera rituxinLevi garrawayKrish patelLymphoma programSwedish cancer institute in seattleGlobal product development at rocheEvaluating glofitamabCombination with gemcitabineParticipants withRefractory diffuse largeb cellSwedish cancer instituteGlobal product development

CHMP Supports Approval of Subcutaneous Atezolizumab for All Current IV Indications

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of subcutaneous atezolizumab for all indications in which the intravenous formulation is approved, including certain types of lung, liver, bladder, and breast cancer

Levi garrawayGlobal product development at rocheEuropean unionEuropean commissionEuropean medicines agencyMedicinal productsHuman useGlobal product developmentMedicinal products for human useSubcutaneous atezolizumab

Significant Phase 2 Findings Support Zilebesiran as Anti-Hypertension Treatment

Significant Phase 2 Findings Support Zilebesiran as Anti-Hypertension Treatment
pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.

Levi garrawayZilebesiran kardiaGlobal product development at rocheGlobal product developmentRenin angiotensin aldosterone system

Subcutaneous Atezolizumab Approved in Great Britain for All Intravenous Indications

Great Britain’s Medicines and Healthcare Products Regulatory Agency has approved subcutaneous atezolizumab for all indications in which the intravenous formulation of the drug has been approved, including select types of lung, bladder, breast, and liver cancers.

United kingdomGreat britainLevi garrawayGlobal product development at rocheEuropean medicines agencyHealthcare products regulatory agencyGlobal product developmentNorthern islandEuropean medicinesGlobal oncologyImmuno oncology

vimarsana © 2020. All Rights Reserved.